RJT
GYRE icon

Raymond James Trust’s Gyre Therapeutics GYRE Stock Holding History

Raymond James Trust’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,467
Closed -$55K – 1148
2021
Q1 		$55K Buy
+1,467
New +$67.1K ﹤0.01% 1088
2020
Q4 		– Sell
-1,867
Closed -$60K – 1052
2020
Q3 		$60K Buy
+1,867
New +$73.1K ﹤0.01% 963

Other funds holding GYRE

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Raymond James Trust's GYRE Position: Q2 2021 in Review

Raymond James Trust sold out of Gyre Therapeutics (GYRE) in Q2 2021, closing a stake of 1,467 shares — an estimated $55K sold.

Raymond James Trust first reported a position in GYRE in Q3 2020 and held it in 2 quarters. The position peaked at $60K in Q3 2020. 69 funds tracked by Wall St. Rank hold GYRE as of Q2 2021.

  • Raymond James Trust reported no remaining Gyre Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Raymond James Trust sold 1,467 Gyre Therapeutics shares in Q2 2021, an estimated $55K.
  • Raymond James Trust first reported a position in Gyre Therapeutics in Q3 2020 and held it in 2 quarters.
  • Raymond James Trust's Gyre Therapeutics position peaked at $60K in Q3 2020.
  • 69 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2021.

Based on Raymond James Trust's 13F filing for Q2 2021, filed 20 Jul 2021.